Skip to main content
Donate

About FAST

Global Science Summit & Gala

SAVE THE DATE!

The 18th Annual Global Science Summit & Gala is November 7-8, 2025 at the Renaissance Orlando at SeaWorld in Orlando, Florida.

Registration opens Summer 2025.

6 Photos from the 2024 Global Science Summit and Gala weekend.

This is the biggest science and drug development event devoted to Angelman syndrome.

learn more

The Global Science Summit is preceded by the Translational Research Symposium and Angelman Syndrome Biomarker and Outcome Measure Consortium (A-BOM) meeting which will be on November 6, 2025 in Orlando, FL. This is an event for the research community by invite only. If you are interested in attending, email events@cureangelman.org.

TRS-ABOM

What is A-BOM?

Registration sign at TRS-ABOM in 2024.

International Guests

If you live outside of the United States and will need a visa to travel to the US, please consider applying now. If you would like FAST to write you a letter of invitation for you to enclose with your visa application, we are happy to do so. To request a letter of invitation, please email events@cureangelman.org and provide the full names of the people in your family who will attend.

Sponsors and Exhibitors

  • If your business or organization is interested in sponsoring or exhibiting at the event, please email events@cureangelman.org.

2024 Global Science Summit & Gala Recap

FAST Angelman Syndrome News

A high sensitivity assay of UBE3A ubiquitin ligase activity from Dr. Albert Keung’s Lab

FAST Poland Organized the 1st Polish National Angelman Syndrome Conference

FAST Italy Hosts Its First Scientific Symposium on Angelman Syndrome

Introducing the Angelman Syndrome Global Community Advisory Board (CAB)

International Angelman Day 2025: Round-Up

2025 AS Congressional Advocacy Day: Legislative Priorities

FAST announces the launch of two biotech companies to advance investigational gene-targeted therapies f...

February 2025: Advocacy updates and actions to take

CAN Spotlight: Raye’s Birthday Fundraiser

FAST-Affiliated Research Program at UCLA is awarded $5.8M to advance gene therapy for Angelman syndrome.

CAN Community Spotlight: Joelene

Introducing the Innovation Seed Grant: Supporting Early-Stage Angelman Syndrome Research

FAST Germany’s Wachgeküsst campaign

Update on Advocacy Efforts and Ways to Get Involved in 2025

Ultragenyx Announces First Patient(s) Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angel...

FAST Spain Awards First Research Grant

FAST and ASF Advocate for Crucial Legislation

CAN Spotlight: Paddle Party for a Purpose

CAN Spotlight: 2nd Annual Hole Out Fore Heath Golf Tournament

FAST and ASF Announce their Partnership with the Institute for Gene Therapies

A high sensitivity assay of UBE3A ubiquitin ligase activity from Dr. Albert Keung’s Lab

FAST Poland Organized the 1st Polish National Angelman Syndrome Conference

FAST Italy Hosts Its First Scientific Symposium on Angelman Syndrome

Introducing the Angelman Syndrome Global Community Advisory Board (CAB)

International Angelman Day 2025: Round-Up

2025 AS Congressional Advocacy Day: Legislative Priorities

FAST announces the launch of two biotech companies to advance investigational gene-targeted therapies f...

February 2025: Advocacy updates and actions to take

CAN Spotlight: Raye’s Birthday Fundraiser

FAST-Affiliated Research Program at UCLA is awarded $5.8M to advance gene therapy for Angelman syndrome.

CAN Community Spotlight: Joelene

Introducing the Innovation Seed Grant: Supporting Early-Stage Angelman Syndrome Research

FAST Germany’s Wachgeküsst campaign

Update on Advocacy Efforts and Ways to Get Involved in 2025

Ultragenyx Announces First Patient(s) Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angel...

FAST Spain Awards First Research Grant

FAST and ASF Advocate for Crucial Legislation

CAN Spotlight: Paddle Party for a Purpose

CAN Spotlight: 2nd Annual Hole Out Fore Heath Golf Tournament

FAST and ASF Announce their Partnership with the Institute for Gene Therapies

Disclaimer

This website contains information for a broad audience and may include information on current and upcoming programs that are not yet approved or accessible The information provided is for general informational purposes only and is not intended as medical advice, diagnosis, or treatment. While FAST strives to provide accurate and up-to-date information, the content on this site may not always reflect the most current research or clinical guidelines. The inclusion of clinical trial information, treatments or specific healthcare providers does not imply endorsement, recommendation or guarantee of safety, efficacy, or availability. Reliance on any information provided by this website is solely at your own risk. FAST disclaims any liability for any errors or omissions in the information provided or for any decisions made based on this information. For personalized medical advice or specific health concerns including participation in any clinical trial, please consult a qualified healthcare professional.